Mechanism by which imiquimod inhibits the migration of fibroblasts in pathological scars and its targets

doi:10.12307/2022.616

Abstract

Abstract: BACKGROUND: Studies have shown that imiquimod has a certain prevention and therapeutic effect on pathological scar, but its target and exact mechanism are not clear yet.
OBJECTIVE: To explore and verify the target genes of imiquimod acting on pathological scar, and to observe the effect of imiquimod on the migration ability of scar fibroblasts.
METHODS: Data sets were downloaded from GEO online database and analyzed to screen out the target genes of imiquimod acting on scar tissue. Scar-derived fibroblasts were extracted. The effect of imiquimod on cell migration was detected by cell scratch test and Transwell test. The expression of type 1 collagen and PCOLCE was detected by western blot assay.
RESULTS AND CONCLUSION: By screening the results of data set integration, two target genes, PCOLCE and ARHGEF25, were obtained. The results of cell experiment in vitro showed that compared with the control group, imiquimod treatment group significantly decreased the scratch healing rate and the number of migrated cells (P < 0.05), and the protein expression levels of type I collagen and PCOLCE in scar fibroblasts were also significantly decreased (P < 0.05). The results confirmed that the inhibitory effect of imiquimod on scar may be related to its down-regulation of PCOLCE expression, reduction of extracellular matrix, and reduction of cell migration rate.

Key words: imiquimod, pathological scar, fibroblast, collagen, cell migration

CLC Number:

Wang Rui, Lyu Tao, Huo Jing, Liu Zhendong, Song Jianbo. Mechanism by which imiquimod inhibits the migration of fibroblasts in pathological scars and its targets[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(20): 3173-3177.

Figures/Tables 5

References

[1] BAO Y, XU S, PAN Z, et al. Comparative Efficacy and Safety of Common Therapies in Keloids and Hypertrophic Scars: A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2020;44(1):207-218.
[2] COENTRO JQ, PUGLIESE E, HANLEY G, et al. Current and upcoming therapies to modulate skin scarring and fibrosis. Adv Drug Deliv Rev. 2019;146:37-59.
[3] KARPPINEN SM, HELJASVAARA R, GULLBERG D, et al. Toward understanding scarless skin wound healing and pathological scarring. Faculty Rev. 2019;8:787.
[4] YANG SW, GENG ZJ, MA K, et al. Comparison of the histological morphology between normal skin and scar tissue. J Huazhong Univ Sci Technolog Med Sci. 2016,36(2):265-269.
[5] SHPICHKA A, BUTNARU D, BEZRUKOV EA, et al. Skin tissue regeneration for burn injury. Stem Cell Res Ther. 2019;10(1):94.
[6] GRABOWSKI G, PACANA MJ, CHEN E. Keloid and Hypertrophic Scar Formation, Prevention, and Management: Standard Review of Abnormal Scarring in Orthopaedic Surgery. J Am Acad Orthop Surg. 2020;28(10):408-414.
[7] WANG ZC, ZHAO WY, CAO Y, et al. The Roles of Inflammation in Keloid and Hypertrophic Scars. Front Immunol. 2020;11:603187.
[8] HUANG C, OGAWA R. Systemic factors that shape cutaneous pathological scarring. FASEB J. 2020;34(10):13171-13184.
[9] AL-SHAQSI S, AL-BULUSHI T. Cutaneous Scar Prevention and Management: Overview of current therapies. Sultan Qaboos Univ Med J. 2016;16(1):e3-e8.
[10] HAYASHI T, FURUKAWA H, OYAMA A, et al. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg. 2012;38(6):893-897.
[11] 徐浩翔,崔盘根.咪喹莫特作用机制和临床应用进展[J].中华皮肤科杂志,2013,46(6):447-449.
[12] BERMAN B, HARRISON-BALESTRA C, PEREZ OA, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. J Drugs Dermatol. 2009;8(5):455-458.
[13] 李晓庆,刘文军,段建兴, 等.手术联合多种干预措施治疗耳部瘢痕疙瘩疗效的网状meta分析[J].中华整形外科杂志,2018,34(12):1010-1019.
[14] 杜启翠,肖文林,孙桂兰, 等.原代培养人增生性瘢痕成纤维细胞的生物学行为[J].中国组织工程研究,2013,17(7):1174-1179.
[15] 吴霞,岑建萍,程浩.咪喹莫特对人疤痕疙瘩来源成纤维细胞增殖及凋亡的影响[J].医学分子生物学杂志,2014,11(4):200-203.
[16] LEE HJ, JANG YJ. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids. Int J Mol Sci. 2018;19(3):711.
[17] WERNER S, KRIEG T, SMOLA H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol. 2007;127(5):998-1008.
[18] WANG ZC, ZHAO WY, CAO Y, et al. The Roles of Inflammation in Keloid and Hypertrophic Scars. Front Immunol. 2020;11:603187.
[19] WISEMAN J, SIMONS M, KIMBLE R, et al. Effectiveness of topical silicone gel and pressure garment therapy for burn scar prevention and management in children: study protocol for a randomised controlled trial. Trials. 2017;18(1):72.
[20] BERMAN B, MADERAL A, RAPHAEL B. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment. Dermatol Surg. 2017;43:S3-S18.
[21] JACOB SE, BERMAN B, NASSIRI M, et al. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol. 2003;149 Suppl 66:62-65.
[22] STASHOWER ME. Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg. 2006;32(3):380-386.
[23] DE MESQUITA CJ, LEITE JA, FECHINE FV, et al. Effect of imiquimod on partial-thickness burns. Burns. 2010;36(1):97-108.
[24] 董达科,陈晓栋,王建力.咪喹莫特对瘢痕疙瘩成纤维细胞增殖和胶原产生的影响[J]. 中华皮肤科杂志,2006,39(10):568-570.
[25] YAN L, WANG LZ, XIAO R, et al. Inhibition of microRNA-21-5p reduces keloid fibroblast autophagy and migration by targeting PTEN after electron beam irradiation. Lab Invest. 2020;100(3):387-399.
[26] LUO L, LI J, LIU H, et al. Adiponectin Is Involved in Connective Tissue Growth Factor-Induced Proliferation, Migration and Overproduction of the Extracellular Matrix in Keloid Fibroblasts. Int J Mol Sci. 2017;18(5):1044.
[27] WITT E, MALIRI A, MCGROUTHER DA, et al. RAC activity in keloid disease: comparative analysis of fibroblasts from margin of keloid to its surrounding normal skin. Eplasty. 2008;8:e19.
[28] PULIDO D, SHARMA U, VADON-LE GOFF S, et al. Structural Basis for the Acceleration of Procollagen Processing by Procollagen C-Proteinase Enhancer-1. Structure. 2018;26(10):1384-1392.
[29] HASSOUN E, SAFRIN M, ZIV H, et al. Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscle and Liver Fibrosis in Mice. PloS one. 2016;11:e0159606.
[30] ZHU Q, GUO W, ZHANG S, et al. Synergistic effect of PCPE1 and sFRP2 on the processing of procollagens via BMP1. Febs Lett. 2019;593(1):119-127.
[31] WONG VW, YOU F, JANUSZYK M, et al. Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars. Ann Plast Surg. 2014; 72(6):711-719
[32] WANG S, ZHONG L, LI Y, et al. Up-regulation of PCOLCE by TWIST1 promotes metastasis in Osteosarcoma. Theranostics. 2019;9(15):4342-4353.
[33] GREENBERG EN, MARSHALL ME, JIN S, et al. Circadian control of interferon-sensitive gene expression in murine skin. Proc Natl Acad Sci U S A. 2020; 117(11):5761-5771.
[34] IMBERTSON LM, BEAURLINE JM, COUTURE AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110(5):734-739.
[35] LI VW, LI WW, TALCOTT KE, et al. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4(6):708-717.
[36] 刘振东,王瑞,李小磊,等.干扰素α-2b抑制瘢痕形成的研究与热点[J]. 中国组织工程研究,2021,25(2):317-321.
[37] LEE JH, KIM SE, LEE AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol. 2008; 47(2):183-186.
[38] YANG SY, YANG JY, HSIAO YC, et al. A Comparison of Gene Expression of Decorin and MMP13 in Hypertrophic Scars Treated with Calcium Channel Blocker, Steroid, and Interferon: A Human-Scar-Carrying Animal Model Study. Dermatol Surg. 2017;43 Suppl 1:S37-S46.